{"preliminary_commentary":{"by_channel":{"x_thread":34,"youtube":7,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05231629\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"MASTER-2","nct_id":"NCT05231629","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=master-2-nct05231629. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MASTER-2","arms":[{"description":"3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients","label":"Arm A","type":"EXPERIMENTAL"},{"description":"AHCT intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients","label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":"AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance in MRD positive patients","label":"Arm C","type":"EXPERIMENTAL"},{"description":"AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance in MRD positive patients","label":"Arm D","type":"ACTIVE_COMPARATOR"},{"description":"Induction - 6 cycles of Dara-VRd in all participants","label":"Arm M","type":"OTHER"}],"collaborators":["Janssen Scientific Affairs, LLC","Sarah Cannon","coMMit, Myeloma Trials, Innovated"],"completion_date":{"date":"2029-12","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Dara-VRd intensification, Dara-R maintenance","otherNames":["darzalex, velcade, revlimid, dexamethasone"],"type":"DRUG"},{"name":"AHCT intensification, Dara-R maintenance","otherNames":["melphalan, darzalex, revlimid"],"type":"DRUG"},{"name":"AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance","otherNames":["melphalan, teclistamab, darzalex"],"type":"DRUG"},{"name":"AHCT intensification, Dara-R consolidation, Dara-R maintenance","otherNames":["melphalan, darzalex, revlimid"],"type":"DRUG"},{"name":"Dara-VRd induction","otherNames":["darzalex, velcade, revlimid, dexamethasone"],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"University of Alabama at Birmingham","official_title":"MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Depth of response obtained with 6 cycles of Dara-VRd","timeFrame":"6 months"},{"measure":"Sustained MRD negativity","timeFrame":"18 months"}],"references":[],"start_date":{"date":"2023-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","url":"https://clinicaltrials.gov/study/NCT05231629"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/master-2-nct05231629"}